MAPLE-BROWN ABBOTT

Maple-Brown Abbott Asia ex-Japan Fund

Monthly Factsheet – 30 November 2021

Overview

The Maple-Brown Abbott Asia ex-Japan Fund (the "Fund") is an actively managed fund that invests in the Asia region excluding Japan. We may also invest in stocks listed outside Asia that conduct the majority of their operations in Asia. The Fund offers investors exposure to a diversified portfolio by country and industry sectors. The Fund is focused on companies that have strong balance sheets, free cash flow generation and good corporate governance. We will only invest in a company where we assess the discount to intrinsic value is sufficiently attractive. The Fund typically holds between 40–60 stocks.

Fund snapshot

Objective

The Fund aims to outperform the MSCI All Countries Asia Excluding Japan Net Index (US\$) over rolling fouryear periods.

Features

- Investment expertise: The Fund is managed by a dedicated and experienced team of Asian equity specialists.
- Investment growth: The Fund aims to deliver long term capital growth.
- Broader investment opportunities: The Fund provides access to investment opportunities, markets and risk management techniques not generally available to individual investors.

Investment philosophy

Value, active, bottom up

PORTFOLIO MANAGER

Will Main



Fund country weight (%)



Top 5 holdings (%)

	i ullu
Taiwan Semiconductor Manufact. Co	7.6
Samsung Electronics	7.1
Tencent Holdings	6.6
NetEase	4.4
Housing Development Finance	3.6

Fund

Portfolio characteristics ¹

	Fund	Market overall ²		Fund	Benchmark
Price: Earnings ratio	11.0	14.0	Monthly volatility $\%$ p.a. ⁴	20.4	20.7
Price: Cash Flow ratio	6.9	9.7	Tracking Error (ex-ante) ⁵	4.8	
Price: Net Tangible Assets ratio	1.3	1.8	Beta vs Benchmark ⁵	0.9	
Dividend yield %	4.0	2.5	Information ratio ⁶	0.0	
Balance sheet strength ³	0.54	0.48			

Risk measures

For latest Fund commentary click here.

Notes:

1 The portfolio characteristics are based on the underlying securities held within the fund/Market overall. The figures shown the Fund are our own estimates for the next twelve months having regard to available information on the underlying companies as at 30 November 2021 and are subject to change without notice. The Market Overall is an estimate for the next twelve months based on estimates from UBS, Macquarie and Maple-Brown Abbott. These figures are based on certain assumptions (including forecasting a company's earnings, profit, cash flows, balance sheet, and estimating payout ratios) which may be inaccurate or impacted by unknown risks. Actual outcomes may vary in a materially positive or negative manner.

 The Market overall data represents our quantitative data which includes 88.4% of the index weight of the stocks in the Benchmark, plus non-Benchmark stocks.

3 Balance sheet strength is calculated as Cash Flow/Total Liabilities. Refer footnote 1 for further detail.

4 Volatility is since inception 19 October 2007. The volatility is calculated for both the Fund and Benchmark. Volatility calculation is annualised and is the standard deviation of monthly returns.

- 5 Source: UBS
 - 6 Information ratio is since inception 19 October 2007. Information ratio is calculated as the Excess return/Tracking error for the fund in base currency (USD).

Want to find out more?

Contacts: Email: Telephone: Facsimile

Website:

Susan Douse susan.douse@douseassociates.com +44 1306 876 192 +44 1306 882 802 maple-brownabbott.com.au Duncan Hodnett <u>dhodnett@maple-brownabbott.com.au</u> +61 2 8226 6220 +61 2 8226 6201 <u>maple-brownabbott.com.au</u> Monthly Factsheet - 30 November 2021

Fund performance (%)⁷

Institutional Euro Class (USD)		ISIN: IE00B284YS39	NAV: EUR 1.5191					
							Since inception	
	1 month	3 months	1 year	3 years p.a.	4 years p.a.	5 years p.a.	p.a.	
							19 Oct 2007	
Fund ⁸	-4.6	-5.7	5.7	6.8	3.3	7.6	3.9	
Benchmark ⁹	-3.9	-6.6	0.4	10.5	5.1	10.5	3.7	
Institutional Euro (EUR)		ISIN: IEOOB284YS39	NAV: EUR 1.5191					
							Since inception	
	1 month	3 months	1 year	3 years p.a.	4 years p.a.	5 years p.a.	p.a.	
							19 Oct 2007	
Fund ⁸	-1.9	-1.1	12.4	7.0	4.8	6.3	5.6	
Benchmark ⁹	-1.2	-2.1	6.7	10.8	6.6	9.2	5.4	
Institutional US Dollar (USD)	ISIN: IE00B284YV67		NAV: USE	0 1.2948				
							Since inception	
	1 mor	nth 3 months		1 year	3 years p.a.	4 years p.a.	p.a.	
							10 Apr 2017	
Fund ⁸	-	4.6 -5.7		5.7	6.8	3.3	5.7	
Benchmark ⁹	-	3.9 -6.6		0.4	10.5	5.1	8.9	

Notes:

7 Past performance is not a reliable indicator of future performance. Source: Maple-Brown Abbott Ltd, MSCI as at 30 November 2021.

8 The Fund's performance is based on the movement in net asset value per share and is before tax and after all fees and charges. Tax credits are not included in the performance figures.

9 Benchmark: MSCI AC Asia ex-Japan Net Index (relevant currency).

Signatory of:



Disclaimer
This document is prepared by Magle-Brown Abbott Limited ("Magle-Brown Abbott") on behalf of Magle-Brown Abbott Funds (c the "UCTS"), an open-ended unbrelia investment company with variable capital and segregated liability between sub-funds, incorporated in teland and authorised by the Central Bank of Ireland as an Undertaking for Collective Investment in Transferable Securities. The Magle-Brown Abbott Funds (c the "Sub-Fund") is a sub-fund of the UCTS and Magle-Brown Abbott ABN 73 001 208 564, Australian Financial Services Licence No. 23729(b) is the UCTS discretionary investment manage and dishibutor. The Information is prohibited or restricted by low, Information in this document is for information proposes only and does not constitute an offer or solicitation by anyone in any jurisdiction. Noting contained on this document is not admetstoric to be treated as, investment and the investment decision, you should seek independent investment He, Igal, tax, accounting or other professional advice as applicable and is before tax and after all fees and charges. Tax credits are not included in the performance in the UCTS may fall and sub-fund and and the all fees and charges. Tax credits are not included belows in responsement and to sol investment in the UCTS may fall and sub-fund and and the all fees and charges. Tax credits are not included belows in responsement and to sol investment in the UCTS may fall and sub-fund and and the all fees and charges. Tax credits are not included belows in responsement and to sol order investments or any forecastor or simulates are not are responsed belows or therement and the solution of their expective delegates, appointed service provides or other responsements and orgenetation and publications of the response and gualifications and qualifications on sol and investment. A any forecastor or simulates are not an exceeding and invested belows in responsed belows in responsed below in the solute and their solute

A sum into y or investion in grant a transmission in the Coll 3 and in the contrast of the con

Swiss investors Important information for Swiss investors.

Important information for Swiss investors. This is an advertising document. The prospectus, the articles of association and the annual and semi-annual reports of the Fund are available only to Qualified Investors free of charge from the Representative. In respect of the Shares distributed in Switzerland to Qualified Investors, place of performance and jurisdiction is at the registered office of the Representative. Swiss Representative. SWiss Representative. SWiss Paymentative FIRST INDEPENDENT FUND SEXVICES LTD, Rubusstrasse 23, CH-8008 Zurich MSCL The MSCL information may only be used for your internal use, may not be registered office of an analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCL information is intended to constitute investment advice or a recommendation to make (or refain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCL information is intended to constitute investment advice or a recommendation to make (or originally, accuracy, completenes, finemeting, completing, stimulements, or products or indices. None of the MSCL information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCL each of its affiliates and each other person involved in or related to compling, computing or creating any MSCL information (collectively, the "MSCL Parties") expressly disclaims all warranties (including, withour limitation, any warranties of originally, accuracy, completenes, fundiments, non-infigurent mechantality and fitness for a particular purpose) with respect to this information. Withour limiting any of the foregoing, in no event shall any MSCLParty have any liability for any direct, indirect, special, indirect, special, indirect, special, indirect, special, indirect, specia

Want to find out more?

Contacts: Email: Telephone: Facsimile Website:

Susan Douse susan.douse@douseassociates.com +44 1306 876 192 +44 1306 882 802 maple-brownabbott.com.au

Duncan Hodnett dhodnett@maple-brownabbott.com.au +61 2 8226 6220 +61 2 8226 6201 maple-brownabbott.com.au